Phase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Principal Investigator
Mitul Gandhi, MDLocations
Fairfax Office
Gainesville Office
Arlington Office
Loudoun Office
Alexandria Office
Learn More About This Trial
Other Relevant Trials
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Principal Investigator
Alexander I. Spira, MD, PhD, FACP(ALKS 4230-007/GOG-3063) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
